Thomas J. Polascik, MD, FACS, presented “Integration of Germline Testing in Prostate Cancer Screening” for the Grand Rounds in Urology audience in November, 2019.
How to cite: Polascik, Thomas J. “Integration of Germline Testing in Prostate Cancer Screening” November, 2019. Accessed Nov 2024. https://grandroundsinurology.com/integration-of-germline-testing-in-prostate-cancer-screening/
Integration of Germline Testing in Prostate Cancer Screening – Summary:
Thomas J. Polascik, MD, FACS, surveys the current status of germline testing for prostate cancer in screening populations, and explains how his institution, Duke University, has been advancing research in this area. He discusses current studies measuring the ability of germline testing to predict outcomes, highlights the Duke algorithm for when and whom to test, and describes challenges for integrating germline testing into the current model of prostate cancer screening.
This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:
Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective
Current Prostate Cancer Genetic Testing Capabilities and Considerations
A Urologist’s Perspective on Germline Testing
ABOUT THE AUTHOR
Thomas J. Polascik, MD, FACS, is Professor of Surgery at Duke University Medical Center and the Director of Surgical Technology at the Duke Prostate and Urological Cancer Center. He is the Founder and Co-Director of the International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, which began at Duke in 2008. Dr. Polascik is the Editor of Imaging and Focal Therapy of Early Prostate Cancer. He is Founder and President of the Focal Therapy Society, as well as Director of Duke’s Society of Urologic Oncology Fellowship Training Program and the Genitourinary Program on Focal Therapy at the Duke Cancer Institute. He is the Medical Director of Duke’s Men’s Health Initiative Screening Event and is a governing member of several medical boards and societies. His clinical and research interests focus on prostate and kidney cancer. He has authored over 350 peer-reviewed manuscripts and book chapters.
